Landon J. Getz receives inaugural GSK EPIC Convergence Postdoctoral Fellowship in Antimicrobial Resistance
EPIC is pleased to announce Landon J. Getz as the recipient of the inaugural GSK EPIC Convergence Fellowship in Antimicrobial Resistance (AMR). Established through a generous gift from GlaxoSmithKline (GSK), the fellowship will support Getz’s innovative and cross-disciplinary research that aims to address the growing threat of AMR through the development of phage therapy.